ERBB2 and breast carcinoma: Combinations of the synthesized compound with docetaxel, a drug from the taxane group included in many adjuvant chemotherapy regimens for oncological diseases, were less effective against the HER2+ breast cancer cell model, and the SS values for such combinations were less than 10 (Fig. 9).